Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase

Clinical Biochemistry

Volumn 46, Issue 1-2, 2013, Pages 148-151

  Braga, Federica ^a,b   Ferraro, Simona ^a   Mozzi, Roberta ^a   Dolci, Alberto ^a   Panteghini, Mauro ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Biological variation; Chromogranin A; Neuron specific enolase

Indexed keywords

CHROMOGRANIN A; NEURON SPECIFIC ENOLASE;

ADULT; ANALYTIC METHOD; ANALYTICAL ERROR; ARTICLE; BIOLOGICAL RHYTHM; BIOLOGICAL VARIATION; BLOOD CHEMISTRY; BLOOD SAMPLING; BLOOD STORAGE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENDER; HUMAN; IMMUNOASSAY; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE; ROOM TEMPERATURE; SENSITIVITY AND SPECIFICITY;

ADULT; CHROMOGRANIN A; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PHOSPHOPYRUVATE HYDRATASE; REFERENCE VALUES; REGRESSION ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871813127     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.09.005     Document Type: Article

References (15)

1. ESMO, Oberg K., Jelic S., ESMO Guidelines Working Group Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 2009, 20:150-153.
2. Brodeur G.M., Pritchard J., Berthold F., Carlsen N.L., Castel V., Castelberry R.P., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993, 11:1466-1477.
3. Dittadi R., Meo S., Gion M. Biological variation of plasma chromogranin A. Clin Chem Lab Med 2004, 42:109-110.
4. Fraser C.G., Harris E.K. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989, 27:409-437.
5. Harris E.K. Effects of intra- and inter-individual variation on the appropriate use of normal range. Clin Chem 1974, 20:1535-1542.
6. Lippi G., Blanckaert N., Bonini P., et al. Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clin Chem Lab Med 2008, 46:764-772.
7. Braga F., Dolci A., Montagnana M., Pagani F., Paleari R., Guidi G.C., et al. Revaluation of biological variation of glycated hemoglobin (HbA1c) using an accurately designed protocol and an assay traceable to the IFCC reference system. Clin Chim Acta 2011, 412:1412-1416.
8. Fraser C.G., Hyltoft Petersen P., Libeer J.C., Ricos C. Proposal for setting generally applicable quality goals solely based on biology. Ann Clin Biochem 1997, 34:8-12.
9. Glinicki P., Kapuścińska R., Jeske W. The differences in chromogranin A (CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods. Endokrynol Pol 2010, 61:346-350.
10. Drivsholm L., Paloheimo L.I., Österlind K. Chromogranin A, a significant prognostic factor in small cell lung cancer. Br J Cancer 1999, 81:667-671.
11. Tsao K.C., Wu J.T. Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas. Clin Chim Acta 2001, 313:21-29.
12. Marotta V., Nuzzo V., Ferrara T., Zuccoli A., Masone M., Nocerino L., et al. Limitations of chromogranin A in clinical practice. Biomarkers 2012, 17:186-191.
13. Gowans E.M.S., Hyltoft Peterson P., Blaabjerg O., Horder M. Analytical goals for the acceptance of common reference intervals for laboratories throughout a geographical area. Scand J Clin Lab Invest 1988, 48:757-764.
14. Oosterhuis W.P. Gross overestimation of total allowable error based on biological variation. Clin Chem 2011, 57:1334-1336.
15. (Accessed April, 2012). http://www.westgard.com/biodatabase1.htm.